{"filing":{"accession_number":"0001654954-26-007840","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-08-25","report_date":"2026-08-25","primary_document":"a9590r.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426007840/a9590r.htm"},"events":[{"id":29312,"run_id":26827,"accession_number":"0001654954-26-007840","anchor_item_number":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"AstraZeneca announced the pricing of a €2.55 billion Eurobond offering on 24 August 2026, consisting of four tranches of fixed-rate notes maturing between 2030 and 2038, issued by its subsidiary AstraZeneca Finance LLC and guaranteed by the parent company. This is a material creation of direct financial obligations under Item 2.03 of the 8-K taxonomy, aligned with the company's long-term funding strategy and expected to close on 1 September 2026.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-08-25","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":31553,"accession_number":"0001654954-26-007840","item_number":null,"item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"AstraZeneca announced the pricing of a €2.55 billion Eurobond offering on 24 August 2026, consisting of four tranches of fixed-rate notes maturing between 2030 and 2038, issued by its subsidiary AstraZeneca Finance LLC and guaranteed by the parent company. This is a material creation of direct financial obligations under Item 2.03 of the 8-K taxonomy, aligned with the company's long-term funding strategy and expected to close on 1 September 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-25T11:05:22.562689+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-08-25"}]}